Cargando…
280 Use of Omalizumab in Chronic Moderate to Severe Persistent Asthma-an Indian Experience
BACKGROUND: The worldwide prevalence of asthma is high and increasing. In India prevalence of asthma is variable from 4% to 20%. Despite ICS plus LABA therapy 72% of asthma patients were uncontrolled or not well controlled in INSPIRE study. Immunoglobulin-E plays a central role in inflammatory casca...
Autores principales: | Ansari, Qamar, Diseases, Chest |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512853/ http://dx.doi.org/10.1097/01.WOX.0000412037.69878.04 |
Ejemplares similares
-
277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
por: Yalcin, Arzu Didem, et al.
Publicado: (2012) -
282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
por: Bergmann, Karl-Christian, et al.
Publicado: (2012) -
276 A 4-Year Follow-up in Children With Moderate/Severe Asthma after Withdrawal 1 Year Omalizumab Treatment
por: Teijeiro, Alvaro, et al.
Publicado: (2012) -
155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012) -
279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)